Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Let’s get back to what it means to do things “clinically”
November 14, 2018
By: Ben Locwin
Contributing Editor, Contract Pharma
I hear a lot about what’s “clinical” or what isn’t, or what’s being done clinically, or clinical assessments. Think for a moment about what this term means to you. It should have a precise meaning, but oftentimes the true meaning is lost amidst a sea of misconception with strong headwinds of nonsense. Getting back to the “Klinikos” The first known use of the term “clinical” was c. 1728. It derives from the Greek klīnikós, which means ‘of the bed.’ This later became klinike (the sick bed), and was drawn into Latin as clinicus (physician that visits patients in their beds). But even those who do this kind of work don’t always get it right. In the Journal of Pediatrics, they have written: “…three of these six foods were actually the cause of symptoms, and upon their elimination, clinical cure was effected.” There are two huge scientific problems with this statement, and in a reputable journal no less. First, nothing can ever be proven to be “cured.” This is instead a statistical hypothesis that must be tested against the empirical evidence, in which case the best that can ever be said is that a condition was “resolved” or “abated.” This is NOT the same thing as “cured” because the null hypothesis is never “proven”—it is either rejected or it fails to be rejected. A medical treatment may be said to be effective if we reject the null hypothesis, which should be a priori written as “there is no difference between the ‘treatment’ group and the ‘no treatment’ group. Falsification of the null hypothesis gives us evidence that there is indeed a difference between the two groups, but can never prove an effect. Second, “clinical cure” is no different from “regular cure.” Something either works or it doesn’t. In cases of use like these, it’s the author’s choice to weigh down their language with hubris. “Clinical” just sounds so important in that journal quote, but something that appears to have an effect in an actual clinic should be expected to have a similar effect in someone’s home, in a shopping mall, or on Mars. Here’s a semi-faulty famous use of the term as well: “Clinical observation supports this contention in many cases.” —Paul Ehrlich, Histology of the Blood, 1900 What were the observations? What data were gathered? The term “supports this contention” should bring to your mind the idea of a null hypothesis. What is the null hypothesis, the contention that’s being investigated? And what does “in many cases” mean? What’s the quantification of “many”? Because something done in a clinical way necessarily involves independent assessments of singular patients, it is ultra-highly subjective, susceptible to opinion, and anecdotally-based. Better medicine comes from better data Good population-based medicine, and good pharmaceutical testing and trials are based on many thousands of data points. So what we typically do in clinical trials is amass many, many investigators’ independent evaluations and pieces of information and combine them together to try to detect a viable signal. This is essentially taking a Grand Mean of many different measured parameters, including subjective ones, and is absolutely fraught with variability. This is the main source of noise in our industry’s trial data. Any good scientist eschews the notion of a qualitative assessment being a good source of data to conduct experimentation. The more we can use personalized medicine, precision medicine, pharmacogenomics, and better measurement paradigms that take human appraisal variability out of the equations, the better the future of medicine will become. It’s nice to see a clinical effect in one or a small number of patients, but remember that virtually every single drug trial shows a positive effect in the placebo group, and so we see every day that people are showing up to clinical visits reporting positive outcomes from null treatment. We can treat patients clinically (at the bedside), but we only know what works by using and improving upon our data measurement paradigms. What really matters is whether or not we can demonstrate evidence that a medical treatment works systematically through randomized controlled trials, which are used specifically to try to reduce the impact of chance in the outputs we measure. If we don’t have this degree of confidence in a treatment—supported by data—then we can’t say a treatment ‘works clinically.’ Period.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !